Photo from wikipedia
Transplant and hematologic malignancy patients have high Coronavirus disease 2019 (COVID‐19) mortality and impaired vaccination responses. Omicron variant evades several monoclonal antibodies previously used in immunocompromised patients. Polyclonal COVID‐19 convalescent… Click to show full abstract
Transplant and hematologic malignancy patients have high Coronavirus disease 2019 (COVID‐19) mortality and impaired vaccination responses. Omicron variant evades several monoclonal antibodies previously used in immunocompromised patients. Polyclonal COVID‐19 convalescent plasma (CCP) may provide broader neutralizing capacity against new variants at high titers. Vaccination increases severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) titer in convalescent donors.
Journal Title: Transplant Infectious Disease
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!